Phaseline

Targets › GSK3A

GSK3A (Glycogen synthase kinase-3 alpha): drug programs, companies and trials

1 program from 1 company in 9 trials: 3 Phase 1, 3 Phase 4, 2 Phase 2, 1 Phase 3; Neurology, Oncology, Other; next expected readout Dec 2026.

Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), CTNNB1/beta-catenin, APC and AXIN1. Requires primed phosphorylation of the majority of its substrates. (UniProt, P49840)

Open in Phaseline: the race on GSK3A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Alzamend NeuroLithium Carbonate (AL001)
Inositol-1(or 4)-monophosphatase 1 inhibitor; Glycogen synthase kinase-3 inhibitor
IMPA1, GSK3A, GSK3BPhase 1Bipolar I Disorder; Healthy; Bipolar II Disorder; Depression, Bipolar …Dec 2026

Conditions

Bipolar I Disorder (1) Healthy (1) Bipolar II Disorder (1) Depression, Bipolar (1) Bipolar Depression (1) Cornelia De Lange Syndrome (1) Cognitive Impairment (1) Parkinson Disease (1) Proven Pathogenic or Probably Pathogenic TBR1 Variant (1)

Modalities

small molecule (1)

Companies

Alzamend Neuro (1)

Related targets

IMPA1 (1) GSK3B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.